Aparna M. Hegde

Hematology

619 19th St S
Birmingham, AL 35249

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: September 02, 2026

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Journal: The New England journal of medicine

Published: May 06, 2026

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.

Journal: Cancer research

Published: March 27, 2026

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.

Journal: bioRxiv : the preprint server for biology

Published: December 25, 2025

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Journal: Nature medicine

Published: November 25, 2025

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.

Journal: Cancer cell

Published: June 18, 2025

RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

Journal: Cancer immunology research

Published: June 18, 2025

Disrupted molecular glue complex drives RAS inhibitor resistance.

Disrupted molecular glue complex drives RAS inhibitor resistance.

Journal: Cell

Published: June 03, 2025

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 24, 2024

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Journal: Journal for immunotherapy of cancer

Published: February 05, 2024

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 06, 2023

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 04, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026